Morepen Laboratories Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹570.13 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.62 per cent from ₹484.72 crore. This corresponds to a year-on-year *(YoY) growth of 34.07 per cent.
Operating Profit
Operating Profit stands at ₹82.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 237.59 per cent from ₹24.45 crore. This corresponds to a year-on-year *(YoY) growth of 241.50 per cent.
PBDT
PBDT stands at ₹82.88 crore, reflecting a quarter-on-quarter *(QoQ) increase of 185.40 per cent from ₹29.04 crore. This corresponds to a year-on-year *(YoY) growth of 237.60 per cent.
Profit Before Tax
Profit Before Tax stands at ₹74.53 crore, reflecting a quarter-on-quarter *(QoQ) increase of 220.01 per cent from ₹23.29 crore. This corresponds to a year-on-year *(YoY) growth of 380.22 per cent.
Net Profit
Net Profit stands at ₹56.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 258.92 per cent from ₹15.70 crore. This represents a 393.87 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Morepen Laboratories Ltd Earnings
- YOY
- QOQ
Morepen Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Morepen Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Morepen Laboratories Ltd Financial Reports
Morepen Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Morepen Labs. | -2.78% | 3.80% | 25.16% | 127.44% | 237.16% | 129.15% |
| Innova Captab | 3.10% | 9.08% | 16.21% | 30.54% | 85.54% | 41.98% |
| Sanofi India | -0.66% | -1.70% | -6.68% | -10.38% | -5.49% | -38.92% |
| Orchid Pharma | 1.78% | 14.90% | 5.98% | 11.34% | 115.31% | 45.91% |
| SPARC | 0.05% | 6.68% | 1.41% | -15.86% | 81.89% | 42.02% |
| Jeena Sikho | 1.54% | 3.67% | 0.72% | -11.89% | -12.44% | -37.78% |
| Senores Pharma. | -0.50% | 0.82% | -8.97% | 7.26% | 94.17% | 92.46% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Sushil Suri
WTD & Executive Director : Sanjay Suri
Independent Non Exe. Director : Praveen Kumar Dutt
Independent Non Exe. Director : Ranjit Khattar
Independent Non Exe. Director : Savita
Independent Non Exe. Director : Sharad Jain
Company Secretary : Vipul Kumar Srivastava